←Back to Expert Scholars
Translational Medicine / 转化医学Hodgkin and T cell Lymphoma
Alison Moskowitz
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Clinical Director, Lymphoma Inpatient Unit
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Alison Moskowitz has led innovative trials of brentuximab vedotin and PD-1 inhibitor combinations in relapsed and refractory Hodgkin lymphoma. Her work has redefined salvage therapy and bridging to transplant in classical Hodgkin lymphoma.
Share:
🧪Research Fields 研究领域
relapsed Hodgkin lymphoma
brentuximab vedotin
checkpoint inhibitor combinations
salvage therapy
transplant eligibility
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Alison Moskowitz 的研究动态
Follow Alison Moskowitz's research updates
留下邮箱，当我们发布与 Alison Moskowitz（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment